Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + vincristine + prednisone
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cyclophosphamide + vincristine + prednisone (often abbreviated as COP) is a combination chemotherapy regimen used primarily in the treatment of certain hematologic malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia[2][3][5]. Cyclophosphamide is an alkylating agent that interferes with DNA replication and cell division. Vincristine is a plant alkaloid that inhibits microtubule formation, thereby blocking mitosis. Prednisone is a synthetic glucocorticoid corticosteroid that induces apoptosis in certain cancer cells and modulates immune responses. The combination exploits different mechanisms to maximize anti-tumor activity and reduce the likelihood of drug resistance.
- Other names
- COP
02
Targets
GR (Glucocorticoid receptor)MicrotubuleDNA
Beyond the preview
Go deeper on cyclophosphamide + vincristine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + vincristine + prednisone.